Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Cap Gbl Regulatory News (PCFT)

Share Price Information for Polar Cap Gbl (PCFT)

Share Price is delayed by 15 minutes
Get Live Data
218.00    -7.00 (-3.11%)
Bid:
218.00
Ask:
228.00
Spread: 10.00 (4.587%)
Market Cap: £355.05m
PCFT Live PriceLast checked at - London Stock Exchange

Intraday Polar Cap Gbl Share Chart

Net Asset Value(s) - Replacement

20 Jun 2025 13:43

RNS Number : 8216N
Polar Capital Global Financials Tst
20 June 2025
 

The following amendment has been made to the 'Net Asset Value' announcement released on 20 June 2025 at 13:02 under RNS No 8178N.

 

Addition of "pence" to 210.62.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

 

POLAR CAPITAL GLOBAL FINANCIALS TRUST PLC

 

Legal Entity Identifier: 549300G5SWN8EP2P4U41

 

 

20 June 2025

 

Continuing Shareholders - Net Asset Value

As at the close of business on 19 June 2025 the unaudited net asset value per ordinary share, calculated in accordance with the guidelines of the Association of Investment Companies, was 210.62 pence (cum income). For the avoidance of doubt, this net asset value per ordinary share has been calculated assuming the Tender Offer has gone unconditional and on the basis of total voting rights of 170,306,377 being the estimated issued share capital (excluding shares held in treasury) following completion of the Tender Offer.

 

 

Tendering Shareholders - Tender Price

As announced earlier on 20 June 2025, the Tender Price per Ordinary Share tendered is 209.43 pence, being equal to the prevailing Net Asset Value per Ordinary Share as at the close of business on 18 June 2025 less the Tender Offer Expenses per Share.

In accordance with the terms of the Tender Offer and the expected timetable, subject to the Secondary Placing up to 132,912,988 Ordinary shares will be repurchased by Stifel Nicolaus Europe Limited on 24 June 2025 and all such shares will then be repurchased by the Company pursuant to the Repurchase and Placing Agreement and placed into treasury.

 

Secondary Placing - Secondary Placing Price

 

As announced earlier on 20 June 2025, the Secondary Placing Price per Ordinary Share is 210.47 pence, which represents 100.5 per cent. of the Tender Price

Capitalised terms used, but not defined, in this announcement have the same meaning as given in the Circular dated 14 May 2025.

 

For further information, please call:

Sabrina Yim (Investment Trust Operations Department) 

Tracey Lago/Jumoke Kupoluyi (Polar Capital Secretarial Services) Polar Capital Partners Limited

Tel: 020 7227 2700

IMPORTANT INFORMATION

Stifel Nicolaus Europe Limited ("Stifel"), is authorised and regulated in the United Kingdom by the FCA, and is acting exclusively for the Company and no-one else in relation to the Tender Offer or the matters referred to in this announcement and will not be responsible to anyone other than the Company for providing the protections afforded to customers of Stifel nor for providing advice in relation to the Tender Offer or the matters referred to in this announcement. Nothing in this paragraph shall serve to exclude or limit any responsibilities which Stifel may have under the Financial Services and Markets Act 2000 (as amended) or the regulatory regime established thereunder.

ANY DECISION TO PARTICIPATE IN THE SECONDARY PLACING SHOULD ONLY BE MADE ON THE BASIS OF AN INDEPENDENT REVIEW BY A PROPOSED PLACEE OF THE COMPANY'S PUBLICLY AVAILABLE INFORMATION. NEITHER STIFEL NOR ANY OF THEIR AFFILIATES ACCEPT ANY LIABILITY ARISING FROM THE USE OF, OR MAKE ANY REPRESENTATION AS TO THE ACCURACY OR COMPLETENESS OF, THIS ANNOUNCEMENT OR THE COMPANY'S PUBLICLY AVAILABLE INFORMATION. THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS SUBJECT TO CHANGE IN ITS ENTIRETY WITHOUT NOTICE UP TO THE CLOSING DATE.

In member states of the European Economic Area, any offer of the Ordinary Shares if made pursuant to the Secondary Placing ("Placing Shares") will be directed exclusively at persons who are "qualified investors" within the meaning of Article 2(E) of the Prospectus Regulation. For these purposes, the expression "Prospectus Regulation" means Regulation (EU) 2017/1129 (and amendments thereto). In the United Kingdom the Secondary Placing is available only to, and will be engaged in only with, persons who are "qualified investors" within the meaning of Article 2(E) of the Prospectus Regulation as it forms part of the law of England and Wales by virtue of the European Union (Withdrawal) Act 2018 and who are (i) investment professionals falling with Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order"), or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) other persons to whom an offer of the Placing Shares may otherwise be lawfully communicated (all such persons together being referred to as "relevant persons"). Persons who are not relevant persons should not take any action on the basis of this announcement and should not act or rely on it.

The Placing Shares have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "US Securities Act") or under any the securities laws of any state of or other jurisdiction of the United States and may not be offered, sold, resold, transferred or delivered, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States. The Placing Shares will be offered and sold solely in "offshore transactions" to institutional investors who are located outside the United States and are not US Persons within the meaning of and pursuant to Regulation S under the US Securities Act. No public offering of securities is being made in the United States.

Notice to US Shareholders

The Tender Offer is being made in the United States in accordance with the requirements of Regulation 14E under the US Securities Exchange Act of 1934, as amended (the "US Exchange Act") to the extent applicable and otherwise in accordance with the requirements of UK legislation. The Tender Offer is not subject to the requirements of Regulation 14D under the US Exchange Act. Accordingly, the Tender Offer will be subject to disclosure and other procedural requirements, including with respect to withdrawal rights, offer timetable, settlement procedures and timing of payments, that may be different from those applicable under US domestic tender offer procedures and law.

In accordance with normal UK market practice and pursuant to Rule 14e-5(b) of the US Exchange Act, the Company, its nominees, its brokers (acting as agents) or any of their respective affiliates may from time to time make certain purchases of, or arrangements to purchase, shares in the Company outside the United States, other than pursuant to the Tender Offer, before or during the period in which the Tender Offer remains open for acceptance. These purchases may occur either in the open market at prevailing prices, or in private transactions at negotiated prices. Any information about such purchases will be disclosed as required in the United Kingdom and, if required, will be reported to the Regulatory Information Service of the London Stock Exchange and will be available on the London Stock Exchange website at http://www.londonstockexchange.com/exchange/news/marketnews/market-news-home.html.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVPKKBNBBKDCAB
Date   Source Headline
28th Feb 202411:30 amRNSNet Asset Value(s)
27th Feb 202412:31 pmRNSNet Asset Value(s)
26th Feb 20245:11 pmRNSTransaction in Own Shares
26th Feb 202412:29 pmRNSNet Asset Value(s)
23rd Feb 20245:26 pmRNSTransaction in Own Shares
23rd Feb 20241:26 pmRNSNet Asset Value(s)
22nd Feb 20245:19 pmRNSTransaction in Own Shares
22nd Feb 20241:00 pmRNSNet Asset Value(s)
21st Feb 202412:34 pmRNSNet Asset Value(s)
20th Feb 20245:12 pmRNSTransaction in Own Shares
20th Feb 202412:09 pmRNSNet Asset Value(s)
19th Feb 202412:30 pmRNSNet Asset Value(s)
16th Feb 20245:17 pmRNSTransaction in Own Shares
16th Feb 202412:24 pmRNSNet Asset Value(s)
16th Feb 20247:00 amRNSFinal Results
15th Feb 20245:11 pmRNSTransaction in Own Shares
15th Feb 202412:12 pmRNSNet Asset Value(s)
14th Feb 202412:00 pmRNSNet Asset Value(s)
13th Feb 20245:16 pmRNSTransaction in Own Shares
13th Feb 202411:41 amRNSNet Asset Value(s)
9th Feb 20245:43 pmRNSTransaction in Own Shares
9th Feb 202412:37 pmRNSNet Asset Value(s)
8th Feb 20245:32 pmRNSTransaction in Own Shares
8th Feb 202411:46 amRNSNet Asset Value(s)
8th Feb 20249:56 amRNSHolding(s) in Company
7th Feb 20245:09 pmRNSTransaction in Own Shares
7th Feb 202412:06 pmRNSNet Asset Value(s)
6th Feb 20245:26 pmRNSTransaction in Own Shares
6th Feb 202412:34 pmRNSNet Asset Value(s)
5th Feb 20245:45 pmRNSTransaction in Own Shares
5th Feb 20242:44 pmRNSTop Fifteen Equity Holdings and Exposures
5th Feb 20242:25 pmRNSTop Fifteen Equity Holdings and Exposures
5th Feb 202412:13 pmRNSNet Asset Value(s)
2nd Feb 20245:18 pmRNSTransaction in Own Shares
2nd Feb 202412:31 pmRNSNet Asset Value(s)
1st Feb 20245:18 pmRNSTransaction in Own Shares
1st Feb 20242:54 pmRNSTotal Voting Rights
1st Feb 202412:17 pmRNSNet Asset Value(s)
31st Jan 20245:12 pmRNSTransaction in Own Shares
31st Jan 202412:17 pmRNSNet Asset Value(s)
30th Jan 20245:31 pmRNSTransaction in Own Shares
30th Jan 202412:58 pmRNSBlock listing Interim Review
30th Jan 202412:01 pmRNSNet Asset Value(s)
29th Jan 20245:30 pmRNSHolding(s) in Company
29th Jan 20245:26 pmRNSTransaction in Own Shares
29th Jan 202412:13 pmRNSNet Asset Value(s)
26th Jan 202412:20 pmRNSNet Asset Value(s)
25th Jan 202411:52 amRNSNet Asset Value(s)
24th Jan 202412:26 pmRNSNet Asset Value(s)
23rd Jan 20245:18 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.